FDG-PET/CT and prediction of anti-PD-1/PD-L1 antibody in lung cancer

Not Applicable

• Conditions: ung cancer; Lung cancer

• Registration Number: JPRN-jRCTs031180036
• Lead Sponsor: Kaira Kyoichi

Brief Summary

Metabolic assessment by MTV or TLG was superior to morphological changes on CT for predicting the therapeutic response and survival at 4 weeks after PD-1 blockade in patients with advanced NSCLC.

Detailed Description

Not available

Study Timeline

• Study Start: 2018-11-01
• Study Completion: 2022-01-31
• Results First Posted: 2022-07-01
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 58

Inclusion Criteria

1)Pathologically confirmed advanced non-small cell lung cancer (NSCLC)
2)Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2
3)Patient with evaluable lesion based on RECIST
4)Written informed consent

Exclusion Criteria

1)Pregnant woman
2)Patients with obvious interstitial pneumonia or pulmonary fibrosis in the chest X-ray.
3)Patients with collagen vascular disease or autoimmune diseases
4)Other cases attending physician it is determined unsuitable for registration of the study

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
1)Changeing of SUVmax, MTV and TLG, and the efficacy of anti-PD-1/PD-L1 antibody such as nivolumab or pembrolizumab. <br><br>2)Evaluation after 4weeks and 9weeks from administration of anti-PD-1/PD-L1 antibody.

Secondary Outcome Measures

Name	Time	Method
Overall survival and progression-free survival